Abstract
We are currently experiencing a vital discussion around best medical treatment for vascular patients. Introduction to the market of direct acting oral anticoagulants (DOACs) offered new options for cardiovascular patients. With these drugs our view broadened: from sole patency and limb salvage rates, our emphasis changed to a broader view to minimise major adverse cardiovascular events and major adverse limb events for a better quality of life and longer overall life expectancy. A strong drive for this development came from two studies: the COMPASS study for stable cardiovascular patients,1 and the VOYAGER study, which had a sole focus on unstable vascular patients in need of intervention or surgery.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
